GB811717A - Improvements in or relating to therapeutic compositions - Google Patents
Improvements in or relating to therapeutic compositionsInfo
- Publication number
- GB811717A GB811717A GB21001/55A GB2100155A GB811717A GB 811717 A GB811717 A GB 811717A GB 21001/55 A GB21001/55 A GB 21001/55A GB 2100155 A GB2100155 A GB 2100155A GB 811717 A GB811717 A GB 811717A
- Authority
- GB
- United Kingdom
- Prior art keywords
- penicillin
- per cent
- amount
- sodium
- dibenzylethylenediamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A therapeutic composition comprises a water-insoluble penicillin salt in finely-divided form, polyvinyl-pyrrolidone in amount from about 0.05 to 2.0 per cent, lecithin in amount from about 0.2 to about 5.0 per cent, a parenterally acceptable water-soluble buffer in amount from about 0.5 to 10 per cent, an alkali metal salt of carboxymethylcellulose in amount from about 0.1 to 3 per cent, all by weight of the penicillin salt, and a preservative. Specified penicillin salts include procaine penicillin, dibenzylethylenediamine penicillin; N-benzyl-N1 - (3 - ethoxy - 4 - hydroxy) - benzylethylenediamine penicillin; 2-chloroprocaine penicillin and N,N1 - di - (4 - methoxybenzyl) - ethylenediamine penicillin. Polyvinylpyrrolidone of average molecular weight 40,000 is preferred. Suitable buffers include sodium citrate, sodium acetate, sodium lactate and alkali metal salts of inorganic acids such as mono- and di-basic sodium phosphates. Specified preservatives include the methyl, propyl and butyl esters of p-hydroxybenzoic acid, sodium bisulphite, and quaternary ammonium compounds such as benzalkonium chloride. A stable polyhydroxy alcohol such as sorbitol or mannitol may also be included. A minor proportion of a solubility depressant (e.g. procaine hydrochloride when procaine penicillin is employed, or dibenzylethylenediamine acetate when dibenzylethylenediamine penicillin is employed) may also be included in the compositions. The dried preparation is suitable for extemporaneous compounding with water to form aqueous suspensions for injection purposes. An example is included.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US811717XA | 1954-07-28 | 1954-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB811717A true GB811717A (en) | 1959-04-08 |
Family
ID=22162533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB21001/55A Expired GB811717A (en) | 1954-07-28 | 1955-07-20 | Improvements in or relating to therapeutic compositions |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB811717A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005028032A1 (en) * | 2003-09-18 | 2005-03-31 | Scimed Life Systems, Inc. | Injectable therapeutic formulations |
US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
US7906125B2 (en) | 2003-09-18 | 2011-03-15 | Boston Scientific Scimed, Inc. | Solid or semi-solid therapeutic formulations |
US8263109B2 (en) | 2005-05-09 | 2012-09-11 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
-
1955
- 1955-07-20 GB GB21001/55A patent/GB811717A/en not_active Expired
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005028032A1 (en) * | 2003-09-18 | 2005-03-31 | Scimed Life Systems, Inc. | Injectable therapeutic formulations |
US7906125B2 (en) | 2003-09-18 | 2011-03-15 | Boston Scientific Scimed, Inc. | Solid or semi-solid therapeutic formulations |
US7862552B2 (en) | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
US8263109B2 (en) | 2005-05-09 | 2012-09-11 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
US8753620B2 (en) | 2005-05-09 | 2014-06-17 | Boston Scientific Scimed, Inc. | Injectable bulking compositions |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB1026778A (en) | 2-benzyl-2-imidazoline compounds and compositions including them | |
KR960007599A (en) | Compositions with stable shelf life and easy water solubility of injectable cephalosporins | |
US2436184A (en) | Pharmaceutical jelly | |
GB847570A (en) | Shampoo compositions | |
GB811717A (en) | Improvements in or relating to therapeutic compositions | |
KR880001154B1 (en) | The stability method of antibiotics | |
US2498200A (en) | Stabilized thiamin | |
GB1247711A (en) | Antibacterial agents and a process for the preparation thereof | |
US2643998A (en) | Stable antibiotic solutions | |
US2720482A (en) | Stabilized streptomycin solutions | |
GB999121A (en) | Repository antimalarial compositions | |
GB705343A (en) | Improvements in or relating to aqueous suspensions of procaine penicillin | |
GB797237A (en) | Composition for reducing period of anesthesia | |
US2556688A (en) | Pharmaceutical methionine composition | |
GB978485A (en) | Iron preparations for intramuscular injection | |
GB886094A (en) | Novel diiodo-pyridones and compositions containing them | |
IE35323L (en) | Tropan-3-ol derivatives | |
GB816592A (en) | A method for the preparation of stable magnesium solutions of high concentration | |
GB639173A (en) | Improvements in or relating to aqueous solutions containing soapless detergents | |
GB1084440A (en) | Improvements in or relating to (2-aminocycloalkyl) hydroquinones and the manufacturethereof | |
GB1252993A (en) | ||
GB862537A (en) | Anti-microbial compositions | |
GB871456A (en) | Prevention of caking of common salt | |
GB964448A (en) | A new or improved cleaning and sterilising composition | |
GB956360A (en) | A pharmaceutical composition for use as a contraceptive and process for making same |